Senior Research Officer

Dr Eleanor Jane Eiffe

School of Medical Sciences

Dr Eiffe is a medicinal chemist with over ten years' experience in the biotech industry. Her career in drug development has encompassed everything from bench chemistry, to in silico drug design, to the preparation of regulatory submissions and patent applications, through to the management of chemistry manufacturing projects from the laboratory scale to GMP. Dr Eiffe's current focus is designing small molecules that target isoforms of the actin binding protein, tropomyosin, as well as managing the anti-tropomyosin drug development program at TroBio Therapeutics.


  • Journal articles | 2019
    Janco M; Rynkiewicz MJ; Li L; Hook J; Eiffe E; Ghosh A; Böcking T; Lehman WJ; Hardeman EC; Gunning PW, 2019, 'Molecular integration of the anti-tropomyosin compound ATM-3507 into the coiled coil overlap region of the cancer-associated Tpm3.1', Scientific reports, vol. 9, pp. 11262,
    Journal articles | 2017
    Currier MA; Stehn JR; Swain A; Chen D; Hook J; Eiffe E; Heaton A; Brown D; Nartker BA; Eaves DW; Kloss N; Treutlein H; Zeng J; Alieva IB; Dugina VB; Hardeman EC; Gunning PW; Cripe TP, 2017, 'Identification of cancer-targeted tropomyosin inhibitors and their synergy with microtubule drugs', Molecular Cancer Therapeutics, vol. 16, pp. 1555 - 1565,
    Journal articles | 2015
    Iskander G; Wood K; Eiffe E; Yee EMH; Black DSC; Kumar N, 2015, 'Ritter reactions of isoflavanols: A facile route to 4-amidoisoflavans', Tetrahedron Letters, vol. 56, pp. 1941 - 1943,
    Journal articles | 2015
    Iskander G; Wood K; Eiffe E; Yee EMH; Black DS; Kumar N, 2015, 'ChemInform Abstract: Ritter Reactions of Isoflavanols: A Facile Route to 4-Amidoisoflavans.', ChemInform, vol. 46, pp. no - no,
    Journal articles | 2014
    Eiffe E; Pasquier E; Kavallaris M; Herbert C; Black DSC; Kumar N, 2014, 'Synthesis, anti-cancer and anti-inflammatory activity of novel 2-substituted isoflavenes', Bioorganic and Medicinal Chemistry, vol. 22, pp. 5182 - 5193,
  • Conference Posters | 2016
    Stehn J; Mariana A; Failes T; Ashokakumar V; Eiffe E; Heaton A; Hook J; Sivanandhan D; Arndt G; Gunning P; Brown D, 2016, 'Synergistic action of first-in-class anti-tropomyosin compound, ATM-3507 (Anisina) and microtubule targeting inhibitors in pre-clinical models of non-small cell lung cancer (NSCLC)', Munich, GERMANY, Vol. 69, pp. S116 - S116, presented at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Munich, GERMANY, 29 November 2016 - 02 December 2016,
    Conference Abstracts | 2015
    Stehn J; Currier M; Chen D; Eiffe E; Heaton A; Hook J; Gunning P; Cripe T, 2015, 'First-in-class cytoskeletal targeting drug, Anisina, enhances effectiveness of microtubule inhibitors in a preclinical model of neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Fort Lauderdale, FL, Vol. 76, presented at AACR Special Conference on Advances in Pediatric Cancer Research - From Mechanisms and Models to Treatment and Survivorship, Fort Lauderdale, FL, 09 November 2015 - 12 November 2015,